NecstGen has partnered with Paris-based biotech Astraveus to evaluate the Lakhesys™ Benchtop Cell Factory™, a microfluidic-based platform aiming to simplify and scale CAR-T production. The collaboration will test the system’s potential to reduce cost, footprint, and manual steps in a GMP setting.
The partnership strengthens NecstGen’s role in advancing cell therapy manufacturing and highlights Astraveus’ vision for decentralized, efficient production.
Read more: https://necstgen.com/necstgen-and-astraveus-collaborate-to-evaluate-benchtop-cell-factory-technology-for-scalable-car-t-manufacturing/
MIMETAS, a leading organ-on-a-chip company, has announced the publication of a new peer-reviewed study that marks a major advance in cardiovascular disease research. The study,...
What if you could design something that acts like an antibody, but cheaper, more stable, and made entirely with chemistry? Two LACDR researchers, Sebastian Pomplun and Matthias...
Leiden Bio Science Park welcomed a high-level Shanghai delegation, led by Vice Mayor Liu Duo, marking a key step toward international collaboration in life sciences. The visit, initiated by Shanghai, showcased mutual interest in innovation and partnership.